Drug intelligence / Profile preview

CHELATEXX for Autism

Development stage: Preclinical
Lead developer: Chelatexx
Modality: Small Molecules
Administration: Oral

Overview

**CHELATEXX for Autism** is an oral, preclinical Chelatexx therapeutic protocol proposed for **autism spectrum disorder**. The company describes a gut-binder approach intended to reduce colonic production and systemic absorption of gut-derived neurotoxic ammonia associated with dysbiosis. Activated charcoal is intended to adsorb ammonia in the gastrointestinal tract; the autism protocol also lists vitamin C and modified citrus pectin as recommended binders. The public materials describe separate CHELATEXX capsules and CHELATEXX VIT-C tablets taken with meals rather than a fully characterized single fixed-dose formulation. ([chelatexx.com](https://chelatexx.com/chelatexx-for-autism))

Other names: CHELATEXX for Autism

Beyond the preview

Go deeper on CHELATEXX for Autism.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHELATEXX for Autism.

Explore the full profile